Phase I study of AMG 509, a STEAP1 x CD3 T-cell recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
Year: 2021
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: William Kevin Kelly, David William Pook, Leonard Joseph Appleman, David Michael Waterhouse, Lisa Horvath, William Jeffery Edenfield, Nobuaki Matsubara, Daniel Costin Danila, Rahul Raj Aggarwal, Daniel Peter Petrylak, A. Oliver Sartor, Christopher Joseph Sumey, Nabil Adra, Andrew J. Armstrong, Fu-Chih Cheng, Julia Stieglmaier, Hosein Kouros-Mehr, Tanya B. Dorff
Institutions: Thomas Jefferson University, Monash University, UPMC Hillman Cancer Center, Oncology Hematology Care, Chris O’Brien Lifehouse, Prisma Health, Greenville Memorial Hospital, National Cancer Center Hospital East, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Yale Cancer Center, Tulane University, Sanford Health, Indiana University School of Medicine, Duke University, Duke Medical Center, Amgen (United States), Amgen (Germany), City Of Hope National Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Amgen
OpenAlex ID: W4247936085